Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada
16 juil. 2024 08h30 HE
|
Biodexa Pharmaceuticals PLC
July 16, 2024 Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage...
Preliminary Results for the Year Ended 31 December 2023
19 avr. 2024 08h00 HE
|
Biodexa Pharmaceuticals PLC
19 April 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2023 Biodexa...